Education
About Us
Working with TipRanks
Follow Us
HeartBeam (BEAT)
NASDAQ:BEAT
Earnings Data
Report Date
May 08, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.16Last Year’s EPS
-0.17Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 13, 2025
|% Change Since: -0.99%
|Next Earnings Date:May 08, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements, such as FDA clearance, successful fundraising, and strong market potential. Challenges include increased cash outflows and uncertainties in the FDA review timeline. However, the positive aspects significantly outweigh the negatives, indicating strong progress and future potential.Company Guidance
During the HeartBeam, Inc. Fourth Quarter and Full Year 2024 Financial Results Conference Call, the company highlighted several key metrics and developments. HeartBeam's net cash used in operating activities for FY 2024 was $14.5 million, which represented a 20% increase year over year, primarily due to investments in R&D and achieving FDA clearances. The company completed an $11.5 million public offering, resulting in a pro forma cash balance of $12.6 million at the end of 2024. HeartBeam is preparing for commercialization, with a strategic focus on aligning cash resources with key milestones, including a second FDA clearance expected by the end of 2025. The company's go-to-market strategy targets the direct patient pay market, particularly within concierge medicine, estimating an opportunity worth $250 to $500 million in annual revenue. Additionally, HeartBeam has initiated an early access program to refine clinical workflows and establish a sales funnel. The company aims to manage cash burn prudently while preparing for significant milestones and potential commercial launch.FDA Clearance Achieved
HeartBeam, Inc. received foundational FDA clearance for its system, a major milestone demonstrating acceptance of their novel approach.
Successful Public Offering
HeartBeam completed an $11.5 million public offering without warrants, showcasing strong support from existing and new investors.
Clinical Study Presentations
Results from pivotal studies were accepted for presentation at key conferences, including the Heart Rhythm Society Annual Meeting.
Market Expansion Strategy
HeartBeam outlined its go-to-market strategy focusing on the direct patient pay market, estimated at $1.3 to $2.6 billion annually.
Diamond Pinnacle Health Care Award
HeartBeam was awarded the Diamond Pinnacle Health Care Award in medical device innovation, its third award in the past year.
---
BEAT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
BEAT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 13, 2025 | $2.02 | $2.05 | +1.49% |
| Nov 07, 2024 | $2.33 | $2.57 | +10.30% |
| Aug 14, 2024 | $2.27 | $2.31 | +1.76% |
| May 09, 2024 | $2.01 | $1.96 | -2.49% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does HeartBeam (BEAT) report earnings?
HeartBeam (BEAT) is schdueled to report earning on May 08, 2025, TBA Not Confirmed.
What is HeartBeam (BEAT) earnings time?
HeartBeam (BEAT) earnings time is at May 08, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BEAT EPS forecast?
BEAT EPS forecast for the fiscal quarter 2025 (Q1) is -0.16.
---